IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped After careful consideration, our company has decided to revise the overall development strategy for IBI310 and discontinue further registration research for this project. Consequently, the ongoing screening process will be terminated, and this decisi

Conditions

Colorectal Cancer

Interventions

BIOLOGICAL: IBI310 (anti-CTLA-4 antibody)
BIOLOGICAL: Sintilimab(anti-PD-1 antibody)

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.